Home Cart Sign in  
Chemical Structure| 2242470-43-3 Chemical Structure| 2242470-43-3

Structure of DCZ0415
CAS No.: 2242470-43-3

Chemical Structure| 2242470-43-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

DCZ0415 is a TRIP13 inhibitor that disrupts non-homologous end joining repair and inhibits NF-κB activity, demonstrating significant anticancer effects in both in vitro and in vivo models of multiple myeloma, particularly suitable for developing anti-myeloma drugs.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of DCZ0415

CAS No. :2242470-43-3
Formula : C23H20N2O2
M.W : 356.42
SMILES Code : O=C1N(C2=CC=C(C=C2)CC=3C=CN=CC3)C(=O)C4C5C=CC(C14)C6CC56
MDL No. :MFCD03349596

Safety of DCZ0415

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of DCZ0415

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
RKO cells 10 and 20 µM 24 h To evaluate the effect of DCZ0415 on cell cycle, results showed that DCZ0415 caused G2/M phase cell cycle arrest. Mol Oncol. 2022 Apr;16(8):1728-1745
SW480 cells 10 and 20 µM 48 h To evaluate the effect of DCZ0415 on apoptosis, results showed that DCZ0415 induced apoptosis. Mol Oncol. 2022 Apr;16(8):1728-1745
HCT116 cells 10 and 20 µM 48 h To evaluate the effect of DCZ0415 on apoptosis, results showed that DCZ0415 induced apoptosis. Mol Oncol. 2022 Apr;16(8):1728-1745
human HTII-280+ AT2 cells 5 μM 2, 4, 8 days significantly reduced VIM protein expression and delayed its onset Biochim Biophys Acta Mol Basis Dis. 2025 Mar;1871(3):167572
human HTII-280+ AT2 cells 5 μM 4 days prevented EMT, reduced α-SMA expression, and increased HTII-280 expression Biochim Biophys Acta Mol Basis Dis. 2025 Mar;1871(3):167572
NCI-H929 cell line 9.64 μM Evaluate the antiproliferative activity of DCZ0415 on NCI-H929 cell line, with an IC50 value of 9.64 μM. RSC Med Chem. 2025 May 6
PDAC cells (S2VP10, PANC-1, MIA PaCa2, BxPC-3) 10 or 20 µM 10 days To assess the effect of DCZ0415 on PDAC cell colony formation, results showed that DCZ0415 reduced the numbers of colonies formed by PDAC cells. Neoplasia. 2024 Jan;47:100951
PDAC cells (PANC-1, MIA PaCa2, Bx-PC-3, S2VP10) 1-30 µM 48 or 96 h To evaluate the inhibitory effect of DCZ0415 on PDAC cell growth, results showed that DCZ0415 reduced PDAC cell growth in a dose- and time-dependent manner. Neoplasia. 2024 Jan;47:100951
RPMI-8226R5 cells 0.2-3.2 µM 72 h DCZ0415 in combination with bortezomib showed synergistic effects, significantly reducing cell viability. Haematologica. 2024 Apr 1;109(4):1206-1219
H929R cells 0.2-3.2 µM 72 h DCZ0415 in combination with bortezomib showed synergistic effects, significantly reducing cell viability. Haematologica. 2024 Apr 1;109(4):1206-1219
OCI-MY5 cells 0-20 µM 72 h DCZ0415 significantly reduced p-RPS3 levels, indicating that the TRIP13/RPS3 axis might be involved in DCZ0415-induced cell death. Haematologica. 2024 Apr 1;109(4):1206-1219
ARP-1 cells 0-20 µM 72 h DCZ0415 significantly reduced p-RPS3 levels, indicating that the TRIP13/RPS3 axis might be involved in DCZ0415-induced cell death. Haematologica. 2024 Apr 1;109(4):1206-1219

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice CRC xenograft model Intraperitoneal injection 25 mg/kg Every other day for 12 times To evaluate the effect of DCZ0415 on tumor growth, results showed that DCZ0415 significantly inhibited tumor growth. Mol Oncol. 2022 Apr;16(8):1728-1745
NSG mice PDAC subcutaneous and orthotopic models Intraperitoneal injection 25 mg/kg Every other day until the end of the experiment To evaluate the inhibitory effect of DCZ0415 on PDAC tumor growth and metastasis, results showed that DCZ0415 reduced tumor weight and volume, and decreased metastasis. Neoplasia. 2024 Jan;47:100951
Nude mice MM xenograft model Subcutaneous injection 50 mg/kg Twice per week, continuous treatment DCZ0415 treatment was pivotal in re-sensitizing drug-resistant MM cells in vivo, significantly inhibiting tumor growth. Haematologica. 2024 Apr 1;109(4):1206-1219

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.81mL

0.56mL

0.28mL

14.03mL

2.81mL

1.40mL

28.06mL

5.61mL

2.81mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories